By the same authors

Decision rules for cost-effectiveness analysis in low- and middle-income countries: Panel

Research output: Contribution to conferenceOther

Standard

Decision rules for cost-effectiveness analysis in low- and middle-income countries : Panel . / Faria, Rita; Revill, Paul; Glassman, Amanda ; Kingkaew, Pritaporn; Mejía, Aurelio; Wilkinson, T.

2014. HTAi 11th Annual Meeting, Washington, United States.

Research output: Contribution to conferenceOther

Harvard

Faria, R, Revill, P, Glassman, A, Kingkaew, P, Mejía, A & Wilkinson, T 2014, 'Decision rules for cost-effectiveness analysis in low- and middle-income countries: Panel ' HTAi 11th Annual Meeting, Washington, United States, 14/06/14 - 18/06/14, .

APA

Faria, R., Revill, P., Glassman, A., Kingkaew, P., Mejía, A., & Wilkinson, T. (2014). Decision rules for cost-effectiveness analysis in low- and middle-income countries: Panel . HTAi 11th Annual Meeting, Washington, United States.

Vancouver

Faria R, Revill P, Glassman A, Kingkaew P, Mejía A, Wilkinson T. Decision rules for cost-effectiveness analysis in low- and middle-income countries: Panel . 2014. HTAi 11th Annual Meeting, Washington, United States.

Author

Faria, Rita ; Revill, Paul ; Glassman, Amanda ; Kingkaew, Pritaporn ; Mejía, Aurelio ; Wilkinson, T. / Decision rules for cost-effectiveness analysis in low- and middle-income countries : Panel . HTAi 11th Annual Meeting, Washington, United States.

Bibtex - Download

@conference{d3e923579be5469490b35fbdcada832e,
title = "Decision rules for cost-effectiveness analysis in low- and middle-income countries: Panel",
abstract = "Background (100 max 100):Economic evaluation is a tool to guide decisions on how to best use the available resources to improve health. A common rule is to compare the additional costs and health gains of an intervention against a threshold. However, this raises questions about what appropriate thresholds should be in particular contexts and how decisions should relate to the fuller set of choices that face policy-makers. These issues are particularly challenging in low- and middle-income countries (LMICs) for which financial, human and health system constraints are often more severe and for which the availability of information is much more limited. Panel session description and objectives:This panel will debate the appropriate methods for assessing value for money of healthcare interventions. Paul Revill will critique prevailing methods and present a framework for informing a fuller range of policy decisions in LMICs. Rita Faria will show how to estimate the upper-bound for the threshold using readily available data with application to the Colombian context. Pritaporn Kingkaew will present Thailand’s experience on the use of economic evaluation for the selection and price negotiation of medicines. Aurelio Meija will present the challenges and opportunities faced by Colombia in the incorporation of cost-effectiveness evidence in the decision-making process. Tommy Wilkinson will present how NICE International works with LMICs to help shape health technology assessment to their particular contexts. Amanda Glassman will chair the discussion. Attendees will gain an understanding of the specific challenges and opportunities around making decisions on value for money in LMICs.",
author = "Rita Faria and Paul Revill and Amanda Glassman and Pritaporn Kingkaew and Aurelio Mej{\'i}a and T Wilkinson",
year = "2014",
language = "English",
note = "HTAi 11th Annual Meeting ; Conference date: 14-06-2014 Through 18-06-2014",

}

RIS (suitable for import to EndNote) - Download

TY - CONF

T1 - Decision rules for cost-effectiveness analysis in low- and middle-income countries

T2 - Panel

AU - Faria, Rita

AU - Revill, Paul

AU - Glassman, Amanda

AU - Kingkaew, Pritaporn

AU - Mejía, Aurelio

AU - Wilkinson, T

PY - 2014

Y1 - 2014

N2 - Background (100 max 100):Economic evaluation is a tool to guide decisions on how to best use the available resources to improve health. A common rule is to compare the additional costs and health gains of an intervention against a threshold. However, this raises questions about what appropriate thresholds should be in particular contexts and how decisions should relate to the fuller set of choices that face policy-makers. These issues are particularly challenging in low- and middle-income countries (LMICs) for which financial, human and health system constraints are often more severe and for which the availability of information is much more limited. Panel session description and objectives:This panel will debate the appropriate methods for assessing value for money of healthcare interventions. Paul Revill will critique prevailing methods and present a framework for informing a fuller range of policy decisions in LMICs. Rita Faria will show how to estimate the upper-bound for the threshold using readily available data with application to the Colombian context. Pritaporn Kingkaew will present Thailand’s experience on the use of economic evaluation for the selection and price negotiation of medicines. Aurelio Meija will present the challenges and opportunities faced by Colombia in the incorporation of cost-effectiveness evidence in the decision-making process. Tommy Wilkinson will present how NICE International works with LMICs to help shape health technology assessment to their particular contexts. Amanda Glassman will chair the discussion. Attendees will gain an understanding of the specific challenges and opportunities around making decisions on value for money in LMICs.

AB - Background (100 max 100):Economic evaluation is a tool to guide decisions on how to best use the available resources to improve health. A common rule is to compare the additional costs and health gains of an intervention against a threshold. However, this raises questions about what appropriate thresholds should be in particular contexts and how decisions should relate to the fuller set of choices that face policy-makers. These issues are particularly challenging in low- and middle-income countries (LMICs) for which financial, human and health system constraints are often more severe and for which the availability of information is much more limited. Panel session description and objectives:This panel will debate the appropriate methods for assessing value for money of healthcare interventions. Paul Revill will critique prevailing methods and present a framework for informing a fuller range of policy decisions in LMICs. Rita Faria will show how to estimate the upper-bound for the threshold using readily available data with application to the Colombian context. Pritaporn Kingkaew will present Thailand’s experience on the use of economic evaluation for the selection and price negotiation of medicines. Aurelio Meija will present the challenges and opportunities faced by Colombia in the incorporation of cost-effectiveness evidence in the decision-making process. Tommy Wilkinson will present how NICE International works with LMICs to help shape health technology assessment to their particular contexts. Amanda Glassman will chair the discussion. Attendees will gain an understanding of the specific challenges and opportunities around making decisions on value for money in LMICs.

M3 - Other

ER -